Uli Bialucha

Uli Bialucha

Company: Xilio Therapeutics Inc.

Job title: Chief Scientific Officer


Ensuring Translational Success by Futureproofing Your Program: Preclinical Model Selection & Predictive Biomarker Screening 1:00 pm

Dive into discussions on how to maximize the developability of your pre-clinical cytokine efforts through to the clinic and beyond. Explore the intricacies of preclinical models for cytokine therapeutic development and start early thinking for patient selection and dose profiling. Join this workshop to: Navigate what steps can be taken in early development to improve…Read more

day: Pre-Conference Workshop Day

Emerging Learnings From Pre-Clinical Combinations of Tumor-Activated Cytokines With Other Immune-oncology Agents 11:00 am

Revealing the scientific rationale for using cytokines in combination Addressing challenges in combining systemically active cytokines Exploring Pre-clinical data supporting use of Xilio’s tumor-activated cytokines in combination with other IO agentsRead more

day: Conference Day Two

© Copyright 2024 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH.